DocGo and Spect Partner to Reduce Care Gaps and Improve Eye and Vision Health
DocGo (Nasdaq: DCGO) has announced a partnership with Spect to enhance eye and vision health services. This collaboration allows DocGo's mobile health clinicians to use Spect's hand-held retinal cameras, providing scalable, cost-effective diabetic retinopathy and other eye disease screenings at patients' homes and workplaces.
This initiative aims to improve patient care and health plan quality ratings by integrating these screenings into DocGo's services. Spect's platform, known for its ease of use and minimal training requirements, can identify various eye diseases, including glaucoma and macular degeneration. The partnership focuses on supporting DocGo's health plan partnership offerings and addressing care gaps through in-home medical visits.
- Partnership with Spect enhances DocGo's service offerings by integrating advanced eye disease screening technology.
- In-home diabetic retinopathy screening can improve patient care and health plan quality ratings.
- Spect's technology allows for quick, efficient eye exams, identifying diseases in as little as 3 minutes.
- The collaboration aims to address critical care gaps, benefiting patients and health plans.
- None.
DocGo's partnership with Spect signifies a strategic move to enhance mobile health services, particularly for those with diabetes. By integrating Spect’s hand-held retinal cameras into DocGo's existing mobile health infrastructure, the company can improve accessibility for diabetic retinopathy exams. This is particularly relevant as diabetic retinopathy is a leading cause of blindness among adults with diabetes.
Key Benefits: This partnership could significantly improve healthcare outcomes for diabetic patients. Early detection of eye diseases through convenient in-home screenings can help mitigate complications and improve quality of life. This can also lead to better HEDIS quality measures—a set of performance indicators used by health plans to measure care quality. A higher HEDIS rating can attract more contracts with health plans and potentially increase revenue.
Drawbacks: While the initiative is promising, its success will depend on execution. Any logistical issues in deploying this technology or training personnel could impact its effectiveness. Additionally, the partnership's financial impact may not be immediately apparent and could require significant investment.
Short-term Implications: In the short term, the partnership might boost investor confidence as it shows DocGo is innovating and expanding service offerings. The immediate financial impact, however, might be neutral to slightly positive.
Long-term Implications: Long-term, successful integration and widespread adoption of Spect’s devices could solidify DocGo's position in the mobile health market and potentially lead to more lucrative health plan partnerships. This could translate to increased revenue and profitability over time.
The partnership expands DocGo’s ability to support patients and vulnerable populations
“Annual diabetic eye exams are extremely important for people living with diabetes to ensure necessary treatment is received to protect their vision. Unfortunately, this exam is often skipped or delayed. It’s also one of the hardest HEDIS quality measures for health plans to close. By integrating Spect’s scalable and portable technology into DocGo’s technology and services, we can increase the number of eligible members screened, and help improve patient care and health plan quality ratings,” said Dr. James Powell, CEO of DocGo’s Clinical Practice Group. “Our focus is to maximize the results of each patient interaction we have. By integrating this technology, we can offer in-home diabetic eye exams as part of our comprehensive Annual Wellness Visit or together with other screenings personalized for that patient.”
Spect’s solution was selected as DocGo’s preferred solution primarily due to its ease of use, ability to integrate seamlessly into clinical workflows, minimal training curve and availability of a remote Spect specialist to help facilitate the exam. Spect’s platform identifies diabetic retinopathy as well as numerous other eye diseases, such as glaucoma and macular degeneration.
“We’re thrilled to partner with DocGo to provide dilated eye exams for diabetic retinopathy in the home. With Spect, patients have the added convenience of receiving their necessary annual eye exam where they are, to prevent unnecessary blindness caused by diabetic retinopathy,” said Michael Leung, COO and Co-Founder at Spect. “In as little as 3 minutes, we have been able to identify diabetic retinopathy and other eye diseases. Diabetic retinopathy is the leading cause of blindness in adults aged 20–74 and early detection can help reduce a person’s risk by
The partnership will support DocGo’s health plan partnership offerings, with a focus on HEDIS Stars improvement, and mobile primary care. Health plans already contract with DocGo to address gaps in care with in-home medical visits scheduled by DocGo’s in-house patient engagement team. As its preferred solution for diabetic eye exams, DocGo plans to expand its use of Spect devices to help address this critical care gap, as well as explore other opportunities to utilize Spect’s solution as part of a comprehensive eye disease screening program.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
About Spect
Spect is a data science company and the leading provider of Eyecare, Anywhere. Spect’s first product offering is an end-to-end eye disease screening solution. Our mission is to prevent blindness with the early detection of eye disease and to build a platform for healthcare data analytics. Since the eye is the Check Engine Light of the Body™, it serves as a key predictor of eye diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, as well as whole-body diseases, such as stroke, Parkinson's, and more. Our platform trains medical assistants and renders a diagnostic report in minutes. We fill a critical healthcare gap for patients and clinics while delivering best-in-class service and financial outcomes. For more information, please visit www.getspect.com or email us at info@getspect.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including its partnership with Spect. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking. In some cases, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “might,” “will,” “should,” “could,” “can,” “would,” “design,” “potential,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or the negative of these terms or similar expressions.
Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: the ability of the Company to realize the benefits of its partnership with Spect; the Company’s ability to successfully implement its business strategy; the Company’s reliance on and ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s ability to maintain existing contracts; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; and other risk factors included in the Company’s filings with the Securities and Exchange Commission.
The forward-looking statements made in this press release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709347327/en/
Media:
DocGo
Josh Rosenfeld
Avoq
908-770-7204
Jrosenfeld@teamavoq.com
Investors:
Mike Cole
DocGo
949-444-1341
mike.cole@docgo.com
ir@docgo.com
Steve Halper
LifeSci Advisors
646-876-6455
shalper@lifesciadvisors.com
ir@docgo.com
Source: DocGo Inc.
FAQ
What is the significance of DocGo's partnership with Spect for DCGO?
How will Spect's technology benefit DocGo's patients?
What impact does the partnership with Spect have on DocGo's health plan offerings?
How quickly can Spect's platform identify eye diseases?
